Manufacturer: Roche Nz Ltd manufactures Tilcotil.


The uses of Tilcotil include:
Therapeutic Indications:

Tilcotil is indicated for the symptomatic treatment of the following painful inflammatory and degenerative disorders of the musculoskeletal system:

1. rheumatoid arthritis;

2. osteoarthritis;

3. arthrosis;

4. ankylosing spondylitis;

5. extra-articular disorders, e.g. tendinitis, bursitis, periarthritis of shoulders (shoulder-hand syndrome) or hips, strains and sprains;

6. post-operative pain.

Tilcotil tablets are also indicated for:

1. acute gout

2. primary dysmenorrhea.

Dosage and Method of Administration

Standard dosage

After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used.

For all indications except primary dysmenorrhoea, post-operative pain and acute gout, a daily dosage of 20 mg should be given at the same time of day.

The recommended dose for primary dysmenorrhoea is 20 to 40 mg once daily. For post-operative pain the recommended dose is 40 mg once daily up to five days and for acute attacks of gout the recommended dose is 40 mg once daily for two days followed by 20 mg once daily for a further five days.

In treatment of chronic disorders the therapeutic effect of tenoxicam is evident early in treatment and there is a progressive increase in response over time. In chronic disorders, daily doses higher than 20 mg are not recommended since this would increase the frequency and intensity of unwanted reactions without significantly increasing efficacy.

For patients needing long-term treatment a reduction to a daily oral dose of 10 mg may be tried for maintenance.

The tablets should be taken with a glass of water. It is preferable to take this medicine during or immediately after a meal.

Special dosage instructions

In principle, the above dosage recommendations also apply to elderly patients and to patients suffering from kidney or liver disease. Dosage should be minimised in the elderly and in patients with renal impairment.

Because of lack of clinical experience, no dosage recommendations have so far been established for children and adolescents.